跳转至内容

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 11 at 9:00 PM CDT and Saturday, Apr 12 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

Merck
CN
HomeSingle-Use Bioprocessing Film Selection

Single-Use Bioprocessing Film Selection

Single-use technologies are used throughout bioprocessing to improve process flexibility and efficiency and mitigate the risk of product and process contamination. Bioprocessing films are a key component of any single-use technology and, before implementing, the end-user should confirm the characteristics of the film meet the requirements of the bioprocessing operation and the film is compatible with their process fluid. Single-use bioprocessing operations vary widely in scale, complexity, and level of risk: a small bag for sample collection will have different requirements to a 2000 L bioreactor bag which will be different to a header bag in a final fill operation.

Understanding the specific process requirements will guide risk assessment and enable collection of appropriate product data. A key consideration for implementation of any single-use technology is container robustness. Most biomanufacturers dedicate considerable resources on inspecting single-use technologies before they are approved for use in manufacturing and many buy extra bags to account for those rejected during inspection.  Container leaks at any scale are inconvenient, but for large volume applications in particular, film robustness is critical as leaks and compromised seals can result in costly disruptions in the manufacturing environment. 

Our portfolio of single-use containers for bioprocessing are made with either Ultimus® or PureFlex™ films. Containers made with Ultimus® Film are designed for more challenging single-use applications such as mid to large-volume liquid processing applications including storage, transportation, and process intermediate fluid transfer where enhanced bag strength, improved durability and leak resistance is needed.

Containers made with PureFlex™ film can be used throughout manufacturing for low-volume, less critical liquid processing applications. Bags made with PureFlex™ film enable biomanufacturers to scale their process with a single fluid-contact material.

The purpose of this technical article is to provide information on our bioprocessing films to support you in making informed decisions for your process needs. 

Characteristics of Ultimus® Film

Schematic of Ultimus® film structure showing the LDPE outer layer, EVOH gas barrier, Woven nylon and EVA strength layer and ULDPE fluid contact inner layer. The film thickness is 0.0155 in. (0.39 mm).

Ultimus® film was designed to meet the needs of the toughest and highest value single-use applications including large-volume liquid processing and fluid transportation, where extreme durability is needed. Ultimus® Film is available in Mobius® 3D process containers, Mobius® iFlex Bioreactors, Mobius® Power MIX, and Mobius® MIX assemblies.

Our Ultimus® film technology provides enhanced bag strength, improved durability and leak resistance through a novel strength layer reinforced by woven nylon, Figure 1. The fluid contact layer is made up of ultra-low density polyethylene (ULDPE), is free of Irgafos® 168, has a low extractable profile, and supports healthy cell growth. The gas barrier layer is made of ethylene vinyl alcohol copolymer (EVOH). The outer layer of clean low-density polyethylene (LDPE) increases film resistance to leak formation through abrasion, puncture, stretching, and tearing. The woven nylon strength layer is strategically placed between layers of ethylene vinyl acetate (EVA), and significantly increases the overall durability of the film.

Characteristics of PureFlex™ Film

Schematic of PureFlex™ film structure showing the ULDPE outer layer, EVA strength layer, EVOH gas barrier, and ULDPE fluid contact iner layer. The film thickness is 0.01 in. (0.25 mm).

Figure 2. Structure of Pureflex™ film

PureFlex™ film is extremely flexible and can be used for low volume liquid volume applications anywhere in the drug manufacturing process. Manufacturers using PureFlex™ film can scale their process with a single fluid-contact material, thus simplifying the single-use qualification process.

PureFlex™ film contain an ultra-low-density polyethylene (ULDPE) inert fluid contact layer, a low permeability gas barrier layer made of polyethylene vinyl alcohol copolymers (EVOH) and ethylene vinyl acetate (EVA) layers to maintain flexibility, Figure 2.

Comparing Specifications of Ultimus® & PureFlex™ films

 

Tables 1 and 2 compare the specifications of Ultimus® and Pureflex™ films.

Properties

Tests

Ultimus™ Film Average Values

PureFlex™ Film Average Values1

Abrasion Resistance at 500 g

ASTM® F3300 - 18

4007 strokes

 

Puncture Resistance

ASTM® F-1306 - 16

31.3 lbf (139.23N)

 

Flex Durability

ASTM® F-392

No holes at 900 cycles

 

Tensile Strength at Break (psi)

ASTM® D882

5200 psi (35.9MPa)

2700 psi (18.6 Mpa)

Elongation2

ASTM® D882

Test not applicable due to the reinforced structure

570 %

Yield Strength2

ASTM® D882

Refer to tensile strength at break.

1360 psi (9.4 Mpa)

Modulus (Young’s)

ASTM® D882

31.1 kpsi (214.4 Mpa)

 

Toughness2

ASTM® D882

Test not applicable due to the reinforced structure.

9100 in.-lbf/in.3 (63 M J/m3)

Seam Strength

ASTM® D882

57.2 lbf/in (100N:cm)

18 lbf/in. (32 N/cm)

O2 Transmission Rate

ASTM® F1307 at 23 °C

0.009 cc/100 in. /24 h

(0.14 cc/m2/24 h)

0.063 cc/100 in. /24 h

(0.98 cc/m2/24 h)

CO2 Transmission Rate

ASTM® F2476 at 23 °C

<0.065 cc/100 in.2/24 h

(1.01 cc/m2/24 h)

0.13 cc/100 in. /24 h

(92 g/m2/24 h)

Moisture Vapor Transmission Rate (MVTR)

ASTM® F1249 at 23 °C

0.036 g/100 in.2/24 h

(0.558 g/m2/24 h)

0.034 g/100 in. /24 h

(0.53 g/m2/24 h)

Haze

ASTM® D1003

50%

23%

Glass Transition Temperature2

ASTM® D5026

Measurement is not meaningful due to composite structure.

-26 °C

Film Thickness

ASTM® D374

0.0155 in. (0.39 mm)

0.01 in. (0.25 mm)

Operating Temperature Range3

 

 2 - 60 °C

-80 – 60 °C

1PureFlex™ film values reported after gamma irradition at > 45 kGy.

 2Some physical properties impacted by stretch do not apply to Ultimus® film.

3Freezing requires the film to be supported

Table 1. Physical characteristics

Properties

Tests

Ultimus® Film

PureFlex™ Film1

Biological reactivity

USP<88>

Film materials meet the criteria for Biological Reactivity Testing. These tests can be any or a combination of the following test methods: USP<88> Class VI (in vivo), USP<87> (in vitro), ISO 10993-5 (in vitro).

Meets requirements

 

Cytotoxicity

USP<87>

Film materials meet the criteria for Biological Reactivity Testing. These tests can be any or a combination of the following test methods: USP<88> Class VI (in vivo), USP<87> (in vitro), ISO 10993-5 (in vitro).

Meets requirements

 

Bacterial Endotoxin

USP<85>

Film materials meet the criteria for Biological Reactivity Testing. These tests can be any or a combination of the following test methods: USP<88> Class VI (in vivo), USP<87> (in vitro), ISO 10993-5 (in vitro).

Meets requirements

 

Physiochemical Test for

Plastics

Heavy Metals

Buffering Capacity

Non-volatile Residuals

Residue on Ignition

USP<661

Film materials meet the criteria for Biological Reactivity Testing. These tests can be any or a combination of the following test methods: USP<88> Class VI (in vivo), USP<87> (in vitro), ISO 10993-5 (in vitro).

 

 

 

Meets requirements

Meets requirements

Meets requirements

Meets requirements

Aqueous Solutions for

Parenteral Injections

Appearance

Acidity & alkalinity

Reducing Substrate

Transparency, Absorbency

Per Ph. Eur. 3.2.2.1

 

 

 

Meets requirements

 

 

 

Meets requirements

 

Particulate Matter

USP<788>

Meets requirements

Meets requirements

Hemolysis

ISO 10993-4

Meets requirements

Meets requirements

1PureFlex™ film values reported after gamma irradition at > 40 kGy.

Table 2. Biocompatibility characteristics

Film recommendations for different applications

For any high value application, irrespective of volume, the superior strength, robustness, and leak resistance of Ultimus® film makes it the preferred film for single-use processing. Such applications could include mixing, storage, and transportation of process intermediates or drug substance.

For lower value applications involving buffer or cell culture media, at volumes over 100 L scale, we recommend bags and containers made with Ultimus® film to minimize risks from leaks. When volumes are less than 100 L, bags and containers made with time-tested PureFlex™ film will deliver the performance needed and enable easy scalability, Figure 3.

Schematic showing recommended film for single use bioprocessing applications.

Our single-use assembly and mixer bag offerings made of Ultimus® and Pureflex™ films are listed in Table 3.

 

2D Assemblies 

Drum Assemblies 

Collapsible Bin Assemblies 

Stainless Steel Assemblies 

Transport Bin Assemblies 

Scales 

50, 100 mL 

1, 5, 10, 20, 50 L 

50, 100, 200, 500* L 

100, 200*, 250, 500, 1000 L 

100, 250, 500*, 1000*, 2000 L 

200, 500, 1000* L 

PureFlex™ film Standard 

✔*

 

 

 

PureFlex™ film Configurable

✔*

Ultimus® film Standard 

 

 

✔*

✔*

 

Ultimus® film Configurable

 

 

Table 3. A: Assembly offering.

 

Mobius® MIX carriers with standard control box

Mobius® MIX carriers with Ready To Connect control box

Mobius® MIX carriers with Ready To Connect control box

Mobius® Power MIX carriers (standard control and Ready To Connect control box)

Mobius® Power MIX carriers (standard control and Ready To Connect control box)

Scales

10, 50, 100, 200, 500, 1000 L

100, 200, 500 L

1000 L

100, 200, 500 L

1000, 2000, 2500, 3000 L

PureFlex™ film

Standard

Configurable

Ultimus® film

Standard

 


 

 

Configurable

 

 

 

Table 3. B: Mixer bag offering with Ultimus® and Pureflex™ films.

Qualifying and implementing single-use systems in your process

Implementing single-use technologies into a bioprocessing workflow requires close interactions between the biomanufacturer and single-use supplier for both technology selection and ensuring the technology is suitable for the intended application. Information collected from the single use technology supplier is typically utilized by the biomanufacturer for their own process-specific risk assessment.

Successful implementation relies on suppliers qualifying single-use assemblies against industry expectations for numerous quality specifications related to particulates, endotoxin, bioburden, extractables and leachables, sterilization, shelf life, packaging and transport, and integrity testing. While drug manufacturers, may not be directly responsible for all the testing, it is expected that they audit their suppliers and have confidence in their supplier’s manufacturing process, equipment and in-process and release testing practices.

To maintain integrity of the single use technology after leaving the supplier’s facility, manufacturers should have well documented procedures, that align with supplier best practices, on how to receive, inspect, store, unpack, prepare and use the single-use technology, Figure 4.

Single-use system integrity can be impacted during the receiving process, warehouse storage, transportation to the point-of-use, and storage at the point-of-use.

For selecting, testing and validating your filters, assemblies, and single-use systems for drug manufacturing and processing our Single-Use and Filter Validation Services team can help you develop and implement a validation strategy to meet regulatory expectations.

The Emprove® Program provides the documentation needed for implementation of single use systems in biomanufacturing. The detailed product information in the Emprove® Dossiers enables more agile, risk-based decisions, minimizing time and investment from biomanufacturers. The Emprove® Program includes single use components, filters, connectors, and film, as well as a wide range of other products used in bioprocessing such as chromatography resins, cell culture media and chemicals. Description for the dossier contents related to single-use technologies are below:

  • The Emprove® Material Qualification Dossiers (MQD) include product test specifications, release criteria, and regulatory information for the components as well as materials used for component qualification.
  • The Emprove® Quality Management Dossiers (QMD) includes quality and validation information including site qualification, irradiation sterilization process and packaging validations and site qualification. 
  • The Emprove® Operational Excellence Dossier (OED) includes extractables data following BioPhorum and USP <665> guidance to support patient safety evaluation.
  • The Emprove® Component Extractable Reports includes extractables data following USP <665> guidance to support patient safety evaluation. The reports are for single-use components made by third-party suppliers.
  • The Emprove® Advanced Qualification Dossier (AQD) supports custom and configurable assemblies and includes:
  • All available component qualification information and extensive USP <665> extractables data for all the components in the assembly.
  • Information on extractables, bills of material, regulatory statements, component surface area information, original manufacturer information, shelf-life statements, and customer-approved drawings of the assemblies.
  • Data needed by end users to conduct risk assessments and patient safety evaluations of their assemblies
登录以继续。

如要继续阅读,请登录或创建帐户。

暂无帐户?